Faster European drug reviews
U.K.'s National Institute for Clinical Excellence announces plans to expedite reviews. NHS division is "in discussion with the Department of Health over proposals for a revised process allowing more rapid appraisal of important new drugs." The proposals were evaluated by NICE's board at a meeting Sept. 21. The European Medicines Agency has also proposed its new framework for Scientific Advice & Protocol Assessment, which "provides for earlier and greater involvement of internal assessors and external experts." Comments are due by Nov. 22. EMEA projects the new review procedure could reduce response time from 100 days to 70 days (1"The Pink Sheet" July 11, 2005, p. 26)...
You may also be interested in...
The European Medicines Agency is developing a new scientific advice procedure aimed at shortening the timeframe for providing drug development feedback to manufacturers
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.